// App-Quantinova.ai

: Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.

Researchers

Presenter

  • Steven Yip

Principal Investigators

  • Raphael Brandao Moreira

  • Alex Wong

  • Sandy Srinivas

  • Benoit Beuselinck

  • Camillo Porta

  • Hao-Wen Sim

  • D. Scott Ernst

  • Brian I. Rini

  • Takeshi Yuasa

  • Naveen S. Basappa

  • Ravindran Kanesvaran

  • Lori Wood

  • Denis Soulieres

  • Christina M. Canil

  • Anil Kapoor

  • Simon Yuen Fai Fu

  • Toni K. Choueiri

  • Daniel Yick Chin Heng

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Antonio Ermirio de Moraes Oncology Center, Sao Paulo, Brazil

  • University of Alberta, Edmonton, AB, Canada

  • Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • London Health Sciences Center, London, ON, Canada

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Cleveland Clinic, Cleveland, OH

  • National Cancer Centre Singapore, Singapore, Singapore

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • University of Montreal, Montreal, QC, Canada

  • Ottawa Regional Cancer Centre, Manotick, ON, Canada

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • Auckland City Hospital, Auckland, New Zealand

  • Dana-Farber/Harvard Cancer Center, Boston, MA

Locations

  • Canada

  • Brazil

  • United States

  • Belgium

  • Italy

  • Australia

  • Japan

  • Singapore

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Ipilimumab

  • Nivolumab

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved